Literature DB >> 8389196

The site of action of pantoprazole in the gastric H+/K(+)-ATPase.

J M Shin1, M Besancon, A Simon, G Sachs.   

Abstract

Pantoprazole is a pyridinyl-2-methylenesulfinyl-2-benzimidazole derivative. This compound inhibits the vesicular gastric H+/K(+)-ATPase (cytoplasmic side out) under acid transporting conditions by accumulating in the acid space generated by the pump. Pantoprazole is then converted in an acid-catalysed reaction to a cationic sulfenamide and reacts with cysteines available in or from the acidic extracytoplasmic space. This compound binds to the hog gastric H+/K(+)-ATPase with a stoichiometry of 3 nmol per mg protein, resulting in 94% inhibition of ATPase activity. Tryptic cleavage of the intact vesicles which had been reacted with [14C]pantoprazole at a 1 to 4 trypsin to protein ratio removed most of the cytoplasmic domain leaving the pairs of membrane spanning segments and their connecting extracytoplasmic loops intact. The peptides remaining in the membrane were dissolved in SDS and available cysteine residues labelled with fluorescein-5-maleimide. The peptides were separated on Tricine gradient gels, transferred to PVDF membranes and identified by fluorescence and radioactivity. From N-terminal sequence, fluorescence and molecular mass, it is concluded that pantoprazole is able to label both Cys-813 and Cys-822. These cysteines are predicted to be located in the extracytoplasmic loop connecting membrane segments 5 and 6 and in membrane segment 6. The major cytoplasmic tryptic cleavage site at this location moved from position 776 in unmodified enzyme to positions 784 and 792 following pantoprazole labelling, showing that the configuration of this region changed with pantoprazole labelling. A similar result was obtained by reduction of the enzyme with dithiothreitol. Covalent binding of the cationic sulfenamide to this region of the enzyme is able to block the conformation necessary for phosphorylation of the enzyme by ATP, accounting for its inhibitory effect on acid secretion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8389196     DOI: 10.1016/0005-2736(93)90133-k

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  19 in total

Review 1.  Structural similarities of Na,K-ATPase and SERCA, the Ca(2+)-ATPase of the sarcoplasmic reticulum.

Authors:  K J Sweadner; C Donnet
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

Review 2.  Gastric H,K-ATPase as a drug target.

Authors:  Jai Moo Shin; George Sachs
Journal:  Dig Dis Sci       Date:  2006-04-28       Impact factor: 3.199

Review 3.  Molecular mechanisms in therapy of acid-related diseases.

Authors:  J M Shin; O Vagin; K Munson; M Kidd; I M Modlin; G Sachs
Journal:  Cell Mol Life Sci       Date:  2008-01       Impact factor: 9.261

4.  Stress-related Mucosal Disease.

Authors:  Mitchell J. Spirt
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

Review 5.  Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.

Authors:  A Fitton; L Wiseman
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

6.  Membrane disposition of the M5-M6 hairpin of Na+,K(+)-ATPase alpha subunit is ligand dependent.

Authors:  S Lutsenko; R Anderko; J H Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

7.  Benzimidazole covalent probes and the gastric H(+)/K(+)-ATPase as a model system for protein labeling in a copper-free setting.

Authors:  Chelsea J Paresi; Qi Liu; Yue-Ming Li
Journal:  Mol Biosyst       Date:  2016-05

Review 8.  The gastric HK-ATPase: structure, function, and inhibition.

Authors:  Jai Moo Shin; Keith Munson; Olga Vagin; George Sachs
Journal:  Pflugers Arch       Date:  2008-06-06       Impact factor: 3.657

Review 9.  Pharmacological aspects of acid secretion.

Authors:  B I Hirschowitz; D Keeling; M Lewin; S Okabe; M Parsons; K Sewing; B Wallmark; G Sachs
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 10.  Treatment of Helicobacter pylori infection: Current and future insights.

Authors:  Maliheh Safavi; Reyhaneh Sabourian; Alireza Foroumadi
Journal:  World J Clin Cases       Date:  2016-01-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.